Prevalence of Mycoplasma pneumonia Coinfection among Patients with COVID-19: A Systematic Review
Archives of Medical Laboratory Sciences,
Vol. 6 (2020),
20 Dey 2020
,
Page 1-6 (e3)
https://doi.org/10.22037/amls.v6.32399
Abstract
COVID-19 pneumonia signs and symptoms are not specific and it may be similar to other cases of pneumonia caused by other microorganisms such as Mycoplasma pneumonia. This study aimed to investigate the prevalence of M. pneumonia co-infection among patients with COVID-19 by a systematic review and meta-analysis.
Two authors performed the search process independently in Scopus, Web of sciences, and PubMed for studies reporting COVID-19-associated Mycoplasma pneumonia co-infections published in the English language from December 2019 to 1st June 2020. The MeSH terms used in the present review were; “COVID-19”, “co-infection”, “secondary infection”, “2019 novel coronavirus”, “2019-nCoV”, “COVID-19 virus”, “coronavirus disease 2019 virus”, “Mycoplasma pneumoniae”, “M. pneumoniae”, “prevalence”, and “respiratory pathogens”. Data analyzed using Comprehensive Meta-analysis (CMA) software. Heterogeneity among included studies was checked by I2 statistic and the Q2 test. M. pneumonia co-infection was varied between 1 and 40.6% in the included studies. The combined prevalence of M. pneumoniae co-infection among patients with COVID-19 was reported by 17% (95% CI: 7.4–34.3).
Overall, our systematic review and meta-analysis showed a quite high co-infection of M. pneumonia in patients with COVID-19 infection, therefore, routine diagnostic tests are recommended for respiratory pathogens like M. pneumonia, because on-time treatment has a beneficial effect on patient survival. Also, an increasing number of cases of asymptomatic COVID-19 infection, the differentiation and diagnosis of pneumonia caused by COVID-19 from non-COVID-19 pneumonia be considered. It helps avoid unnecessary quarantine and waste of medical resources.
*Corresponding Author: Hakimeh Akbari; Email: akbarih@gerums.ac.ir
Please cite this article as: Akbari H. Prevalence of Mycoplasma pneumonia Coinfection among Patients with COVID-19; a systematic review. Arch Med Lab Sci. 2020;6:1-6 (e3). https://doi.org/10.22037/amls.v6.32399
- COVID-19
- SARS-CoV-2
- Coronavirus
- Coinfection
- Prevalence
- Mycoplasma pneumoniae
How to Cite
References
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. New England Journal of Medicine. 2020.
Singhal T. A review of coronavirus disease-2019 (COVID-19). The Indian Journal of Pediatrics. 2020:1-6.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020;395(10223):497-506.
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Jama. 2020;323(13):1239-42.
Porcheddu R, Serra C, Kelvin D, Kelvin N, Rubino S. Similarity in case fatality rates (CFR) of COVID-19/SARS-COV-2 in Italy and China. The Journal of Infection in Developing Countries. 2020;14(02):125-8.
Wu X, Cai Y, Huang X, Yu X, Zhao L, Wang F, et al. Early Release-Co-infection with SARS-CoV-2 and Influenza A Virus in Patient with Pneumonia, China. 2020.
Lin D, Liu L, Zhang M, Hu Y, Yang Q, Guo J, et al. Co-infections of SARS-CoV-2 with multiple common respiratory pathogens in infected patients. Science China Life Sciences. 2020:1-4.
Li W, Liu Y, Zhao Y, Tao R, Li Y, Shang S. Rapid diagnosis of Mycoplasma pneumoniae in children with pneumonia by an immuno-chromatographic antigen assay. Scientific reports. 2015;5:15539.
Lai C-C, Wang C-Y, Hsueh P-R. Co-infections among patients with COVID-19: the need for combination therapy with non-anti-SARS-CoV-2 agents? Journal of Microbiology, Immunology and Infection. 2020.
Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. International journal of evidence-based healthcare. 2015;13(3):147-53.
Hammerschlag MR. Mycoplasma pneumoniae infections. Current opinion in infectious diseases. 2001;14(2):181-6.
Pereyre S, Touati A, Petitjean‐Lecherbonnier J, Charron A, Vabret A, Bébéar C. The increased incidence of M ycoplasma pneumoniae in F rance in 2011 was polyclonal, mainly involving M. pneumoniae type 1 strains. Clinical Microbiology and Infection. 2013;19(4):E212-E7.
Nir-Paz R, Abutbul A, Moses A, Block C, Hidalgo-Grass C. Ongoing epidemic of Mycoplasma pneumoniae infection in Jerusalem, Israel, 2010 to 2012. Eurosurveillance. 2012;17(8):20095.
Song F, Shi N, Shan F, Zhang Z, Shen J, Lu H, et al. Emerging 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology. 2020;295(1):210-7.
Michael C, Adam B, Xueyan M, Ning Z, Mingqian H, Xianjun Z, et al. Fayad Zahi A. Jacobi Adam, Li Kunwei, Li Shaolin, Shan Hong CT Imaging Features of. 2019:202-7.
Koo HJ, Lim S, Choe J, Choi S-H, Sung H, Do K-H. Radiographic and CT features of viral pneumonia. Radiographics. 2018;38(3):719-39.
Franquet T. Imaging of pulmonary viral pneumonia. Radiology. 2011;260(1):18-39.
Xing Q, Li G-j, Xing Y-h, Chen T, Li W-j, Ni W, et al. Precautions are needed for Patients with COVID-19 with co-infection of common respiratory pathogens. 2020.
Kuiken T, Fouchier R, Schutten M, Rimmelzwaan G, van Amerongen G, van Riel D, et al. van der WS, Escriou N, Manuguerra JC, Stohr K, Peiris JS, Osterhaus AD: Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet. 2003;362:263-70.
Poutanen SM, Low DE, Henry B, Finkelstein S, Rose D, Green K, et al. Identification of severe acute respiratory syndrome in Canada. New England Journal of Medicine. 2003;348(20):1995-2005.
Fan BE, Lim KGE, Chong VCL, Chan SSW, Ong KH, Kuperan P. COVID‐19 and mycoplasma pneumoniae co-infection. American journal of hematology. 2020.
Liu H, Li W, Zhang L, Liu B, Qi C, Fan W, et al. Clinical and CT manifestations of coronavirus disease 2019 (COVID-19): comparison of suspected cases of COVID-19 in isolation and non-COVID-19 pneumonia in a single-center study conducted in Beijing, China.
Blasco ML, Buesa J, Colomina J, Forner MJ, Galindo MJ, Navarro J, et al. Co‐detection of respiratory pathogens in patients hospitalized with Coronavirus viral disease‐2019 pneumonia. Journal of Medical Virology. 2020.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Jama. 2020;323(11):1061-9.
Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. Jama. 2020.
Li H, Chen K, Liu M, Xu H, Xu Q. The profile of peripheral blood lymphocyte subsets and serum cytokines in children with 2019 novel coronavirus pneumonia. Journal of Infection. 2020.
- Abstract Viewed: 213 times
- PDF Downloaded: 101 times